Disease activity and its correlation with anti-mutated citrullinated vimentin antibodies and other factors in rheumatoid arthritis

被引:0
|
作者
Safi, Mohammad-Ayman [1 ]
Fathaldin, Omar [1 ]
机构
[1] King Abdulaziz Univ, Med, Jeddah, Saudi Arabia
关键词
Saudi Arabia; Anti-MCV antibodies; Saudi; Rheumatoid Arthritis; Rheumatoid factor; DAS28-CRP; DAS28-ESR; Disease activity; anti-mutated citrullinated vimentin antibody;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: Our aim was to determine the disease activity (DAS28) and its correlation with anti-Mutated Citrullinated Vimentin antibody (anti-MCV) positivity and other factors in Rheumatoid Arthritis (RA) patients, Saudis and non-Saudis. And to compare Disease Activity measurements using ESR (DAS28-ESR) and CRP (DAS28-CRP). Patients and methods: Retrospectively, data were obtained by files' reviewing, for a period of seven years (2007-2014), at king Abdulaziz university hospital (KAUH), Jeddah, Saudi Arabia. Disease Activity Scores were assessed by DAS28-ESR (104 patients), and together with DAS28-CRP (36 patients). One hundred and four (104) files had complete data for our objectives. Results: DAS28-ESR was high [6 (SD=3)] among non-Saudi patients, moderate among Saudis [4.3 (SD=1.7)] and the total cohort [4.8(SD=2.3]); with significant differences (P=0.000; R-2=11.3%) between Saudi and non-Saudi patients for DAS28. In a linear regression and by correlation analysis; the variables (Sex, age, age-group, anti-MCV positivity) showed no correlations with DAS28, neither for Saudis nor for non-Saudis. Eighty one (81) patients had data concerning presence of comorbid conditions; 34/81(42%) were with comorbid conditions. There was no significant correlation between presence of comorbid condition and disease activity neither for the total cohort (P=0.75) nor for Saudis (P=0.65) and non-Saudis (P=0.70). Conclusion and recommendation: In both Saudi and non-Saudi RA-patients, disease activity can neither be assessed by anti-MCV positivity nor correlated with, comorbidity, sex, age and age groups. DAS28-ESR and DAS28-CRP were significantly correlated. A larger scale study is recommended.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 50 条
  • [41] Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis
    Gonzalez-Lopez, Laura
    Daniel Rocha-Munoz, Alberto
    Ponce-Guarneros, Manuel
    Flores-Chavez, Alejandra
    Salazar-Paramo, Mario
    Nava, Arnulfo
    German Cardona-Munoz, Ernesto
    Selene Fajardo-Robledo, Nicte
    Amali Zavaleta-Muniz, Soraya
    Garcia-Cobian, Teresa
    Ivan Gamez-Nava, Jorge
    [J]. JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014
  • [42] Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity
    Widiyanto, Tulus
    Hidayat, Rudy
    Wibowo, R. M. Suryo Anggoro Kusumo
    Shatri, Hamzah
    [J]. REUMATOLOGIA, 2022, 60 (04): : 252 - 257
  • [43] Autoantibodies to mutated citrullinated vimentin in juvenile rheumatoid arthritis
    Hassfeld, W. G.
    Vinje, O.
    Koenig, K.
    Bayer, P. M.
    Forre, O.
    Dunky, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 439 - 439
  • [44] Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity
    Sockalingam, Sargunan
    Khuan, Chow Sook
    Sthaneshwar, Pavai
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2009, 12 (03) : 211 - 215
  • [45] Anti mutated cytrullinated vimentin antibodies in rheumatoid arthritis.
    Dall'Aglio, Anna Chiara
    Vannini, Antonio
    Fusconi, Marco
    Frisoni, Magda
    Zauli, Daniela
    Bianchi, Francesco Bianco
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S378 - S378
  • [46] Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides
    Innala, Lena
    Kokkonen, Heidi
    Eriksson, Catharina
    Jidell, Erik
    Berglin, Ewa
    Rantapaa-Dahlqvist, Solbritt
    [J]. JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1002 - 1008
  • [47] The value of antibodies to mutated citrullinated vimentin in early arthritis
    Ursum, J.
    van Schaardenburg, D.
    Nielen, M. M. J.
    van der Horst, A. R.
    de Stadt, R. J. van
    Dijkmans, B. A. C.
    Hamann, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 339 - 339
  • [48] Antibodies against citrullinated vimentin in rheumatoid arthritis
    Mathsson, Linda
    Mullazehi, Mohammed
    Wick, Marius C.
    Sjoberg, Olof
    van Vollenhoven, Ronald
    Klareskog, Lars
    Ronnelid, Johan
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (01): : 36 - 45
  • [49] Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis
    Huang, J.
    Zeng, T.
    Zhang, X.
    Tian, Y.
    Wu, Y.
    Yu, J.
    Pei, Z.
    Liu, Y.
    Hu, T.
    Tan, L.
    [J]. BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2020, 77 (01) : 19 - 23
  • [50] Antibodies against mutated citrullinated vimentin fail to predict anti-TNF treatment response in rheumatoid arthritis
    Dejaco, C.
    Duftner, C.
    Klotz, W.
    Schirmer, M.
    Herold, M.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2009, 38 (01) : 66 - 67